Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01047345
Recruitment Status : Completed
First Posted : January 12, 2010
Results First Posted : December 22, 2014
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE January 11, 2010
First Posted Date  ICMJE January 12, 2010
Results First Submitted Date December 12, 2014
Results First Posted Date December 22, 2014
Last Update Posted Date November 27, 2018
Actual Study Start Date  ICMJE February 24, 2010
Actual Primary Completion Date June 10, 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 31, 2016)
  • Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study [ Time Frame: up to 5 days after any vaccination - Base Study ]
    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.
  • Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study [ Time Frame: up to 5 days after any vaccination - Base Study ]
    Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.
  • Percentage of Participants Who Experience a Systemic AE - Base Study [ Time Frame: up to 14 days after any vaccination - Base Study ]
    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.
  • Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study [ Time Frame: up to 14 days after any vaccination - Base Study ]
    An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
  • Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study [ Time Frame: Up to 7 months - Base Study ]
    An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" is defined as a vaccine-related SAE.
  • Percentage of Participants Who Experience a Severe Injection-site AE - Base Study [ Time Frame: up to 5 days after any vaccination - Base Study ]
    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter >2 inches (>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.
Original Primary Outcome Measures  ICMJE
 (submitted: January 11, 2010)
Number of participants who experience serious or non-serious adverse events [ Time Frame: Day 1 to Month 7 ]
Change History Complete list of historical versions of study NCT01047345 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 12, 2014)
Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study [ Time Frame: 4 weeks post-vaccination 3 (Month 7; End of Base Study) ]
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 11, 2010)
Number of participants who are seropositive to each of the HPV types contained in V503 [ Time Frame: Month 7 ]
Current Other Outcome Measures  ICMJE
 (submitted: October 31, 2016)
Percentage of Participants Who Experience an SAE- Extension Study [ Time Frame: up to Month 7 - Extension Study ]
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
Original Other Outcome Measures  ICMJE Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
Official Title  ICMJE A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™
Brief Summary This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE
  • Cervical Cancers
  • Vulvar Cancers
  • Vaginal Cancers
  • Genital Warts
Intervention  ICMJE
  • Biological: V503
    V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
  • Biological: Placebo to V503
    Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
Study Arms
  • Experimental: 9vHPV Vaccine
    Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
    Intervention: Biological: V503
  • Placebo Comparator: Placebo
    Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
    Interventions:
    • Biological: V503
    • Biological: Placebo to V503
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 30, 2012)
924
Original Estimated Enrollment  ICMJE
 (submitted: January 11, 2010)
900
Actual Study Completion Date November 28, 2015
Actual Primary Completion Date June 10, 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Participants Age 12 to 15 Years:

  • Participant is in good health
  • Parent/legal guardian and participant agree to provide study personnel with a primary telephone number for follow-up
  • Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1
  • Participant has not received any other HPV vaccine
  • Participant is not yet sexually active

Participants Age 16 to 26 Years:

  • Participant is in good health
  • Participant agrees to provide a primary telephone number for follow-up
  • Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1
  • Participant has not received any other HPV vaccine
  • Participant has never had Papanicolaou (Pap) testing or has only had normal results
  • Participant has a history of 0 to 4 lifetime sexual partners at enrollment

Exclusion Criteria:

All participants:

  • Participant has a history of severe allergic reaction that required medical intervention
  • Participant has any disorder that would contraindicate intramuscular injections
  • Participant is pregnant
  • Participant is immunocompromised or has an autoimmune condition
  • Participant has had a splenectomy
  • Participant has received any immune globulin product or blood-derived product
  • Participant has participated in a HPV vaccine clinical trial

Participants Age 16 to 26 Only:

  • Participant expects to donate eggs during the study
  • Participant has a history of abnormal cervical biopsy result
  • Participant has a history of HPV-related external genital lesions, external genital cancer, HPV-related vaginal lesions, or vaginal cancer
Sex/Gender
Sexes Eligible for Study: Female
Ages 12 Years to 26 Years   (Child, Adult)
Accepts Healthy Volunteers Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Canada,   Colombia,   Denmark,   Hong Kong,   Mexico,   Puerto Rico,   Sweden,   United States
 
Administrative Information
NCT Number  ICMJE NCT01047345
Other Study ID Numbers  ICMJE V503-006
2010_504 ( Other Identifier: Merck Registration Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP